Ian Udell, MD
Urology · Bozeman, MTNPI 1396065223
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Coloplast at 53.3% of the total. Reporting peaked in 2020 at $4,165 and has fallen 82.3% since, to $738 in 2025.
Across 149 payments — averaging $52.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$4K
- Astellas Pharma US Inc$554
- Johnson & Johnson$526
- Boston Scientific$504
- Endo Pharmaceuticals Inc.$213
- Olympus America Inc.$182
- plus $2K from 35 others
What the payments were for
- Travel & lodging$4,03751%
- Food & beverage$3,42343%
- Education$4285%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$4,191
- XIAFLEX$125
- GENERAL BPH$122
- Enseal X1 5mm$108
- XTANDI$107
How this compares
$7,889 in reported general payments places this provider in the 85th percentile of 45 urology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 11 | $27,421 |
| MyrbetriqMirabegron | 28 | $17,131 |
| Finasteride | 136 | $2,333 |
| Tamsulosin Hcl | 103 | $1,887 |
| Tadalafil | 21 | $477 |
| Meloxicam | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $151 | $27,42111 claims |
| Astellas Pharma US IncMyrbetriq | $554 | $17,13128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 urology providers in Montana.
Other urology in Bozeman
- Jason SkenazyBozeman$12K
- Gregory PrithamBozeman$2K
- John GannonBozeman$2K
- James RobertsonBozeman$145
- Christopher FukudaGreat Falls$19K
- Garrick SimmonsMissoula$16K
- Morris JessopGreat Falls$12K
- Amy McKerrowKalispell$9K
- Lisa BlandBillings$4K
- Jeffrey RedshawMissoula$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.